Drug Response - adverse effect or efficacy

ACE Inhibitor (ACE-I) induced cough

ACE-I induced cough is a common side effect of use of ACE inhibitors, one of the most common class of antihypertensives.  The frequency of ACEI-induced cough varies based on ancestry.  A GWAS of ACEI cough using this algorithm in the eMERGE Network identified KCNIP4 as associated with this phenotype, which was validated in two replication cohorts. 

Cases are those with ACEI cough.  Controls are those exposed to ACEI without adverse events noted and not switched to angiotensin receptor blockers (ARBs).  

Algorithm validated - December 12, 2012.

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Clopidogrel Poor Metabolizers

Note: Attached documents contain full case definition and two different control definitions.  One is for controls with 2 years of follow up, the other for controls with 1 year of follow up.  All available controls with 2 years of follow up were used in Vanderbilt's study.  The control population was supplemented by controls with only 1 year of follow up.  At the time of study, many of the available controls had experienced their qualifying events somewhat recently and 2 years had not yet passed for full follow up.

 

Final

Drug Induced Liver Injury

An algorithm to identify inpatients who have had an acute episode of drug induced liver injury (DILI).

Summary of drug-induced liver injury algorithm

Inclusion criteria

A. Suspect DILI? (NOTE: baseline population is institution specific.  See institution implementation details)

1.     Liver injury AND Exposure to drug (NOTE: medications are institution specific. See institution implementation details)

2.     Temporal relationship of exposure to drug and liver injury diagnosis.

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

PGx medication risk prediction model

This algorithm predicts those who are going to be exposed to warfarin, simvastatin, or clopidogrel as three medications that have known pharmacogenomic influences.  This algorithm was used to select individuals for the Vanderbilt PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment) program, which prospectively tests individuals at risk of needing medications whose efficacy is effected by genetic variants.  

 

For more information on PREDICT, see http://mydruggenome.org.

Owner Phenotyping Groups: 
Final

Statins and MACE

Phenotype Description:  Patients on statins for primary prevention who develop an AMI or 1st AMI. 

Below are algorithms used to identify AMI and 1st AMI cohort at BioVU. If you have questions regarding any of the information presented on this page, you may contact either:

Wei-Qi Wei at wei-qi.wei@vanderbilt.edu

Joshua Denny at josh.denny@vanderbilt.edu

 

             

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Warfarin dose/response

This algorithm identifies patients who have a stable within-range INR (assuming a target INR of 2-3) over at least a three week period and correlates with their warfarin weekly dose.  It is used to identify pharmacogenetics behind warfarin stable dose.

Final